Movchan Oleksii Volodimirovich

Department of Breast cancer and Reconstructive surgery, State Non-commercial Enterprise “National Cancer Institute” of the Ministry of Health of Ukrai, Ukraine

Publications

• Research Article   
  Pegylated liposomal doxorubicin for PIK3CA “wild”, HR+ ,HER 2- , chemoresistant advanced breast cancer
  Author(s): Movchan Oleksii Volodimirovich*, Smolanka Ivan Ivanovich, Lyashenko Andriy Oleksandrovich, Loboda Anton Dmitrovich, Dosenko Irina Viktorivna and Ivankova Oksana Mykolaivna
  
  Introduction: In 2023, nearly 19 million individuals were newly diagnosed with cancer, with breast cancer accounting for 12.7% of all cases. Many efforts were made to reduce the negative effects of doxorubicin while increasing its efficacy. Pegylated Liposomal Doxorubicin (PLD) is a medicine that claims to fulfill these two objectives due of its distinct pharmacokinetic characteristics. Differential activity in patients with PIK3CA-altered vs. PIK3CA-wild-type, estrogen receptor-positive metastatic breast cancer that has progressed during or after antiestrogen treatments. By conducting a comparison analysis with typical anthracycline regimens, this study, using data from earlier studies, tries to understand the possible benefits of PLD. Purpose: To evaluate the efficacy and safety of Pegylated Liposomal Doxorubicin (PLD) in patients with PIK3CA-wild, HR+, HER-, Chemo resistant Advance.. Read More»
  

  Abstract PDF